Proteasome inhibitor MG-132 enhances whole-body protein turnover in rat
| Autor: | Milan Holecek, Tomas Muthny, Ludek Sispera, Miroslav Kovarik |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Proteasome Endopeptidase Complex medicine.medical_specialty Proteome Leupeptins Metabolic Clearance Rate Proteolysis Biophysics Protein metabolism Biology Biochemistry chemistry.chemical_compound Ubiquitin Internal medicine medicine Protein biosynthesis Animals Tissue Distribution Amino Acids Rats Wistar Molecular Biology medicine.diagnostic_test Protein turnover Skeletal muscle Cell Biology Rats medicine.anatomical_structure Endocrinology Proteasome chemistry Organ Specificity Proteasome inhibitor biology.protein Proteasome Inhibitors medicine.drug |
| Zdroj: | Biochemical and Biophysical Research Communications. 345:38-42 |
| ISSN: | 0006-291X |
| DOI: | 10.1016/j.bbrc.2006.04.053 |
| Popis: | Proteasome inhibitors are novel therapeutic agents which may be used in treatment of cancer and other severe disorders. We studied the effect of proteasome inhibitor MG-132 on protein and amino acid metabolism. In MG-132-treated rats we observed a significant decrease in proteasome-dependent proteolysis in skeletal muscle and an increase in whole-body protein turnover (i.e., increase in whole-body proteolysis and protein synthesis). Proteasome-dependent proteolysis was activated in the liver and kidney, protein synthesis increased in skeletal muscle, liver, and kidney. Insignificant changes were found in jejunum and colon. MG-132 administration induced a significant increase in concentration of several amino acids in blood plasma and their decrease in jejunum and colon. We conclude that administration of MG-132 affects both protein anabolic and protein catabolic pathways via the direct effect on proteasome-dependent proteolysis and indirect effect on proteolysis and protein synthesis via unidentified mediators. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect